Company profile for Forty Seven

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At the heart of all we do lies an unyielding dedication to deliver powerful new cancer therapies to patients. Our dedication, present from the very start, has resulted in a drive to understand a new therapeutic approach. Our goal is to leverage our scientific founders’ insights to develop novel therapies that activate the immune system, helping patients defeat their cancer. The therapeutic potential of the innate immune syst...
At the heart of all we do lies an unyielding dedication to deliver powerful new cancer therapies to patients. Our dedication, present from the very start, has resulted in a drive to understand a new therapeutic approach. Our goal is to leverage our scientific founders’ insights to develop novel therapies that activate the immune system, helping patients defeat their cancer. The therapeutic potential of the innate immune system, the first line of defense against cancer, was not well understood and appreciated when Irv Weissman and his colleagues at Stanford University identified CD47-SIRP-alpha as a novel immune pathway.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1490 O'Brien Drive Suite A Menlo Park, CA 94025
Telephone
Telephone
650-352-4150
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://endpts.com/with-forty-seven-co-founder-at-the-helm-new-biotech-spinout-launches-to-target-mutations-potentially-linked-to-numerous-diseases/

Paul Schloesser ENDPTS
27 Jan 2022

https://sfbn.org/san-francisco-biotech-news/2021/10/29/gilead-taps-brakes-on-4-9b-bet-after-rivals-failure-pushing-blood-cancer-data-out-to-2022/

SFBN
30 Oct 2021

https://endpts.com/after-starring-at-ash-last-fall-gileads-new-forty-seven-crew-colors-in-more-promising-data-for-magrolimab-at-asco/

John Carroll ENDPTS
29 May 2020

https://www.gilead.com/news-and-press/press-room/press-releases/2020/5/gilead-and-kite-continue-to-advance-next-generation-cancer-therapies-at-2020-american-society-of-clinical-oncology-annual-meeting

PRESS RELEASE
13 May 2020

https://endpts.com/amid-remdesivir-craze-gilead-finds-time-to-form-another-oncology-pact-looping-in-all-things-nk-cells/

Amber Tong ENDPTS
22 Apr 2020

https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-completes-acquisition-of-forty-seven-inc

PRESS RELEASE
07 Apr 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty